Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Asterisks denote omissions.
FIRST AMENDMENT OF LICENSE AGREEMENT
THIS FIRST AMENDMENT OF LICENSE AGREEMENT (the “First Amendment”) is made and entered
into as of the 20th day of May, 2010 (the “Effective Date”), by and between Idenix Pharmaceuticals, Inc., a
company organized under the laws of the State of Delaware with its principal place of business at 60 Hampshire
Street, Cambridge, Massachusetts 02139, USA (“Idenix”), and ViiV Healthcare Company, successor in interest to
SmithKline Beecham Corporation, doing business as GlaxoSmithKline, a company organized under the laws of the
State of Delaware, with its principal place of business at Five Moore Drive, Research Triangle Park, North
Carolina, 27709, USA (“ViiV”).
W I T N E S S E T H:
WHEREAS, Idenix and SmithKline Beecham Corporation, doing business as GlaxoSmithKline have
previously entered into and executed a License Agreement dated February 4, 2009 (the “Agreement”);
WHEREAS, SmithKline Beecham Corporation assigned the Agreement to ViiV on October 29, 2009 and
WHEREAS, the Parties desire to amend the Agreement as hereafter provided, in accordance with
Section 14.12 of the Agreement.
NOW, THEREFORE, in consideration of the premises, the mutual covenants contained herein and other
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as
1. Capitalized terms used herein but not defined herein will have the meanings ascribed to such terms in the
2. Section 5.2(a) entitled “Development Milestones” will be amended by:
(a) deleting the Milestone Payment for the milestone described in subparagraph (iii) of in the Milestone
Payment chart (Successful Completion of a segment II reproductive toxicity study) and replacing it as
“[**] U.S. Dollars (US $[**]); and
(b) deleting the Milestone Payment for the m